Ductal carcinoma in situ - update on risk assessment and management
- PMID: 26768032
- DOI: 10.1111/his.12796
Ductal carcinoma in situ - update on risk assessment and management
Abstract
Ductal carcinoma in situ (DCIS) accounts for ~20-25% of breast cancers. While DCIS is not life-threatening, it may progress to invasive carcinoma over time, and treatment intended to prevent invasive progression may itself cause significant morbidity. Accurate risk assessment is therefore necessary to avoid over- or undertreatment of an individual patient. In this review we will outline the evidence for current management of DCIS, discuss approaches to DCIS risk assessment and challenges facing identification of novel DCIS biomarkers.
Keywords: breast neoplasms; clinical markers; clinical pathology; patient care management.
© 2015 John Wiley & Sons Ltd.
Comment in
-
The Baader-Meinhof phenomenon in ductal carcinoma in situ of the breast.Histopathology. 2016 Sep;69(3):522-3. doi: 10.1111/his.12977. Epub 2016 May 5. Histopathology. 2016. PMID: 27028714 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
